Abbas Hussain - Oct 2, 2024 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Director
Signature
/s/ Brian Sandstrom, As Attorney-in-Fact
Stock symbol
MRNA
Transactions as of
Oct 2, 2024
Transactions value $
$0
Form type
4
Date filed
10/4/2024, 08:52 AM
Previous filing
Feb 20, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Stock Option (Right to Buy) Award $0 +8.09K $0.00 8.09K Oct 2, 2024 Common Stock 8.09K $63.16 Direct F1
transaction MRNA Stock Option (Right to Buy) Award $0 +5.1K $0.00 5.1K Oct 2, 2024 Common Stock 5.1K $63.16 Direct F2
transaction MRNA Restricted Stock Units Award $0 +1.44K $0.00 1.44K Oct 2, 2024 Common Stock 1.44K Direct F3, F4
transaction MRNA Restricted Stock Units Award $0 +892 $0.00 892 Oct 2, 2024 Common Stock 892 Direct F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option will become fully vested and exercisable on October 2, 2025.
F2 This option will become fully vested and exercisable on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service.
F3 Restricted stock units convert into common stock on a one-for-one basis.
F4 The shares subject to this restricted stock unit award will vest in full on October 2, 2025.
F5 The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service.